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INTRODUCTION
Retroperitoneal tumours are uncommon heterogeneous group of tumours arising either 
primarily in retroperitoneum or representing metastasis from elsewhere.
The  reported  incidence  of  retro  peritoneal  tumour  varies  from 0.3  to  3%.   Surgery 
remains the treatment of choice.  But majority of the tumours are advanced at presentation and 
complete resection possible only in 40-70% of cases.
Our study at Stanley Medical College and Hospital, Chennai for the period of 2003 – 
2006 deals with various presentation and features of retro peritoneal tumours.  Both patient 
factors and surgical factors are taken into consideration.
AIMS AND OBJECTIVES
To study
 The age and sex incidence of retro peritoneal tumours
 The clinical presentation (Signs and Symptoms)
 The diagnostic modalities used in evaluation of retro peritoneal tumors
 The various types of treatment offered
 The immediate post operative complications
 The various histology of retro peritoneal tumours.
REVIEW OF LITERATURE OF RETROPERITONEAL TUMOUR
ANATOMY OF RETROPERITONEUM
Retroperitoneum is  an  actual  and potential  space  between  the  peritoneal  cavity  and 
posterior abdominal wall, containing structures of mesodermal, ectodermal origin with their 
embryonic remnants.
BOUNDARIES OF RETROPERITONEUM
Retroperitoneum has superior, inferior, anterior and posterior boundaries.
Superiorly  12th rib and diaphragm
Inferiorly   Pelvic diaphragm and fascial of levator ani and 
Coccygeus muscles.
Anteriorly  Posterior parietal peritoneum and the space 
between the leaves of small and large bowel mesenteries.
Posteriorly  Vertebral column
Psoas muscles
Quadratus lumborum
Tendinous portion of transverse abdominus.
EMBRYOLOGY
Retroperitoneum  constitutes  the  tissues  derived  from  the  ectoderm,  mesoderm  and 
embryonal remnants.
CONTENTS OF RETROPERITONEUM
Retroperitoneal space is filled with fibrous tissue, fat, loose areolar tissue, blood vessels, 
lymphatic vessels, lymphnodes and nerves.
Kidneys Abdominal aorta
Adrenal glands IVC
Ureter Iliac vessels
Bladder Spermatic and ovarian vessels
Ascending and descending colon Renal vessels
Pancreas, Duodenum Lumbar sympathetic chain
Seminal vesicles Lymphatics and nodes
Vas deferens Fatty areolar tissue
Upper rectum. & Vagina
LYMPHATIC DRAINAGE OF RETROPERITONEUM
Lymphatic drainage of retroperitoneum
Common iliac nodes Aortic (or) lumbar 
nodes
Internal iliac nodes
Lateral aortic Pre-aortic Retro aortic
Coeliac Superior Mesenteric Inferior Mesenteric
PREAORTIC NODES
Lie directly anterior to the abdominal aorta.  
They receive afferents from intermediate nodes associated with subdiaphamatic part of 
GIT, Liver, pancreas and spleen.
Their efferents form the intestinal trunk which enter the cisterna chyli.
LATERAL AORTIC NODES
They lie on either side of abdominal aorta.
They receive afferents from the structures supplied by the lateral and dorsal branches of 
the aorta (Suprarenals, kidneys, testes and ovaries) and from the common iliac nodes.
Their efferents form a lumbar trunk on each side which terminate in Cisterna chili. Few 
efferents may pass to pre aortic nodes.
RETRO AORTIC NODES
No particular drainage area
May be regarded as out lying member of the lateral aortic group.
RETROPERITONEAL TUMOURS
DEFINITION
Retropertitoneal tumours are tumours arising from the fat, muscle tissue, fibrous tissue, blood 
vessels, lymphnodes, nerves, and developmental remnants excluding tumours arising from retro 
peritoneal organs namely kidney, ureter, adrenal and pancreas.
CLASSIFICATION
Retroperitoneal tumours can be classified as
1) Primary retroperitoneal tumours
2) Metastatic tumours
The most frequent tumours diagnosed in the retroperitoneum are :
 Retroperitoneal sarcomas
 Metastatic tumours
 Lymphomas
 Germ cell tumours
 Other neoplasms
CLASSIFICATION OF TUMOURS OF THE RETROPERITONEUM
Tissue Benign Malignant
Tumours arising 
from mesoderm :
Adipose tissue Lipoma Liposarcoma
Fibrous tissue Fibroma Fiborsarcoma
Smooth muscle Leiomyoma Leiomyosarcoma
Striated Muscle Rhabdomyoma Rhabdomyosarcoma
Lymphatics Lymphangioma Lymphangiosarcoma
Primitive 
mesenchyme
Myxoma 
mesenchymoma
Myxosarcoma
Histiocytes Xanthogranuloma Xanthosarcoma 
Malignant fibrous 
histiocytoma
Blood Vessels Hemangiopericytoma
Hemangioendothelioma
Malignant hemangio-
pericytoma
Angiosarcoma
Turmous arising 
from neural tissue
Nerve sheath Neurofibroma
Neurilemmoma
Neurogenic sarcoma
Malignant peripheral 
Nerve sheath tumour
Sympathetic 
nervous system
Ganglioneuroma Neruoblastoma
Paraganglion 
system
Paraganglioma Pheochromocytoma
Tumours arising 
from embryologic 
remnants and 
heterotopic tissue:
Embryologic 
remnants
Teratoma Seminoma
Embryonal carcinoma
Teratoma, Endodermal sinus
Tumour, Chordoma
Heterotopic adrenal 
tissue
Wilm’s tumours 
Adrenocortical carcinoma
Tumour arising 
from lymph nodes 
Lymphomas 
Secondary metastatic deposits
ETIOLOGY OF RETROPERITONEAL TUMOURS
 Majority unknown
 Therapeutic radiation exposure
 Exposure to vinyl chloride, thorium dioxide and other agents.
 Associated with familial disorders like
o Gardner’s syndrome
o Familial retinoblastoma
o Neuro fibromastoses
o Li-fraumani syndrome.
 Germ Line mutation of P53 gene.
PRIMARY RETROPERITONEAL TUMOURS
 75% of primary retroperitoneal tumours arises from mesoderm.
 24% from ectoderm
 1% from embryological remnants.
 Most retro peritoneal tumours are of mesodermal origin.
 Both benign and malignant tumours can arise from many different tissues.
 <25% tumours are benign.  Most common benign tumours are lipoma and epithelial 
cysts.
 Retroperitoneal tumours can be cystic or solid in nature.
 Most of the benign tumours are cystic in nature.
 Most of the malignant tumours are solid in nature.
 Primary retro peritoneal tumours are mainly sarcomas, lymphomas and benign lesions.
 Retroperitoneal sarcomas represents 0.1-0.2% of all malignancies overall, only 10-15% 
of all soft-tissue sarcomas, approximately 40% of all retro peritoneal masses.
1) TUMOURS OF ADIPOSE TISSUE
Most frequently encountered mesenchymal tumours of retroperitoneum.
80%  are abdominal with the perirenal area most frequently involved.
20% are pelvic.
a) LIPOSARCOMA :
More common primary malignant retro peritoneal tumour
More common than retro peritoneal lipomas
Adults commonly affected
Slightly increased incidence in females.
It  is  a  tumour  derived  from  undifferentiated  mesenchymal  cells,  rather  then  the  result  of 
malignant transformation of normal retro peritoneal fat.
Histological varieties include - Well differentiated
- Myxoid
- Pleomorphic
- Dedifferentiated
Well-differentiated  and  myxoid  types  have  good  prognosis.   Pleomorphic  and 
dedifferentiated types have poor prognosis.
Metastasis  occur  commonly  to  the  lungs,  liver  and  serosal  surfaces  (peritoneum), 
infrequently to lymph nodes, mediastinum, heart.
Other tissue types may be found mixed with it leading to diagnosis of Firboliposarcoma, 
Lipomyxosarcoma,
Fibromyxoliposarcoma.
Liposarcomas in other sites can occur simultaneously with, subsequent to or preceding 
retro peritoneal liposarcoma. They are considered multicentric tumours.  Most have involved 
the lower extremities.
b) LIPOMA
 Less common than liposarcoma
 May  contain  fibrous,  myxomatous,  vascular  elements  leading  to  fibrolipoma, 
myxolipoma, fibromyxolipima.
 Adults predominantly affected
 Encapsulation is the rule, but may infiltrate or encompass adjacent structures.
 Recurrences following resection less common than in liposarcomas.
c) HIBERNOMA
 Uncommon, histologically distinct, benign adipose tumours
 Occurs in periadrenal, perirenal, para aortic area which are the sites where brown fat is 
found.
II) TUMOURS ARISING FROM MUSCLE TISSUE :
More frequent in women than men.
More frequent in adults than children
Types : Spindle cell variant
Epitheloid variant.
a) LEIOMYOSARCOMA
 Malignant tumour of smooth muscle
 More common than leiomyoma
 Origin of these tumours include several tissues located in the retroperitoneum, including 
blood vessels, spermatic cord, embryonic wolffian and mullerian duct remnants.
b) LEIOMYOMA
 Benign tumour of smooth muscle
 Exceptionally rare
 If  encountered,  consider  uterine  leiomyoma extending posteriorly,  well  differentiated 
leiomyosarcoma, lymphangiomyoma, angiomyolipoma.
c) ANGIOMYOLIPOMA
 Not strictly a primary retroperitoneal tumour
 Usually originates in the kidney. Rarely occurs in extra renal sites.
 Consists of mature fat & thick-walled blood vessel.
 Confused with leiomyosarcoma because of atypia seen in smooth muscle elements.
d) RHABDOMYOSARCOMA
 Malignant tumour of striated muscle
 Less common than leiomyosarcoma
 Embryonal, alveolar, mixed types occur in children
 Pleomorphic type in adults.
COSTELLO SYNDROME 
Children with mental retardation and retroperitoneal embryonal rhabdomyosarcoma.
e) RHABDOMYOMA
Rhabdomyoma in the retroperitoneum is very rare.
III. TUMOURS ARISING FROM FIBROUS TISSUE
a) BENIGN FIRBOUS TUMOURS
 Previously called as fibromas.  Now classified as fibromatosis.
 Generally solitary in one site; rarely, synchronous in the mesentery, retroperitoneum and 
abdominal wall scar.
 May be associated with familial polyposis,  Gardner’s  syndrome, previous abdominal 
surgery.
 Distinguished from idiopathic fibrosis by lack of inflammatory cell component.
 Distinguished from fibrosarcoma by lack of cell anaplasia and mitosis.
b) MALIGNANT FIRBOSARCOMA
 Rarely reported
 May be associated with hypoglycemia
c) INFLAMMATORY MYOFIBROBLASTIC TUMOUR
Synonyms : Inflammatory pseudo tumour
Inflammatory fibro sarcoma.
It is pseudo sarcomtous proliferation, partially inflammatory in nature that occurs in soft 
tissues and viscera of children and young adults.
It can occur in the retroperitoneum.
It is now classified as intermediate fibrous tumour.
 Histopathologically composed of myofibroblasts and inflammatory cells.
IV) TUMOURS ARISING FROM THE HISTIOCYTES :
a) MALIGNANT FIBROUS HISTIOCYTOMA
 Are a group of sarcoma characterized histologically by storiform or cart-wheel like growth 
pattern of cells derived from tissue histiocytes. More common in adults than children, More 
common in males than females, more frequently in whites than blacks.
 Five Subtypes
o Storiform pleomorphic
o Myxoid
o Gaint cell
o Inflammtory
o Angiomatoid
 Local recurrence and metastasis occur frequently to lungs.
V. TUMOURS ARISING FROM BLOOD VESSELS AND LYMPHATICS
a) BENIGN VASCULAR TUMOURS :
More common than malignant vascular tumours.
LYMPHANGIOMA 
 Most common benign vascular tumours.
 Lymphangiectasia is the dilatation of abnormal lymphatic channels, which have failed to 
establish  normal  communication  with  the  rest  of  the  lymphatic  system.  The  dilated 
lymphatic channels conglomerate and form a unilocular or multilocular cystic mass, known 
as lymphangioma.
 May occur as a part of syndrome consisting of chylous ascities and similar tumours in the 
lung or pleura or as a part of tuberous sclerosis.
OTHER BENIGN VASCULAR TUMOURS ARE:
Haemangiomas
Haemangioendotheliomas
Infantile  haemangioendotheliomas,  thrombocytopenia  and  bleeding  is  known  as  Kasabach 
Meritt Syndrome.
Benign hemangiopericytomas :
Derived from the pericytes. Present usually as bulky silent tumours.
b) MALIGNANT VASCULAR TUMOURS :
 less common than benign vascular tumours
 They include
o Malignant hemangiopericytoma
o Angiosarcoma
May be associated with hypoglycemia due to production of IGF by the tumours.  IGF and IGF-R 
mRNA can be identified in tumour cells even in the absence of clinical hypoglycemia.  Symptoms 
ablate with tumour removal. 
VI.  OTHER MESENCHYMAL TISSUE TUMOURS :
a) MYXOMAS :
Contain  abundant  myxoid  stroma  and  stellate  cells  mimicking  primitive 
mesenchyme.
Differentiated from myxoid liposaroma by lack of florid delicate vascularity.
b)  MESENCHYMOMA :
Reported only in the retropeirtoneum and mesentry.
c)  MYXOSARCOMA :
Malignant counterpart of myxoma. 
VII. TUMOURS ARISING FROM NERVE TISSUE :
a)  NEUROBLASTOMA :
 Most common malignant neurogenic tumours.
 Occurs exclusively in children.
 Extra-adrenal tumours half as frequent as adrenal origin.
 Generally solitary.  May be multiple.
 Prognosis is better in young children and extra adrenal tumours.
b)  GANGLIONEUROMA :
Affects old age group.
Extra-adrenal tumours ate more common than adrenal sites.
c)  MALIGNANT PERIPHERAL NERVE SHEATH TUMOUR :
 It is a malignant tumour arising from a peripheral nerve sheath.
 Histological types :  
Spindle cell
Epithelioid
Combined
 Unless  the  tumour  is  found  arising  from  a  nerve,  it  may  be  misinterpreted  as 
fibrosarcoma or leiomyosarcoma.
d)  NEUROFIBROMA :
e)  NEURILEMMOMA :
Occurs in the retroperitoneum rarely.
Recurrence is common following resection.
f)  PARAGANGLIOMA :
 Tumours of embryological origin arising from the neural crest.
 They can be found in any location along the aorta commonly in the region of organ of 
zukerkandal or in association with the sympathetic chain. 
 These tumours can be non-functioning or functioning. 
 Only 20% of paragangliomas are catecholamine secreting and cause a syndrome similar 
to that of pheochromocytoma.
 They may be multiple and malignant.
 Malignant type spread by blood stream predominantly to bones and lungs.
Some are  familial  (hereditary  paraganglioma)  and occur  as  a  part  of  VHL Von Hippel 
Lindau disease.  
CARNEY’S TRIAD :
 Multiple gastric stromal tumours,
 Pulmonary chordroma,
 Parganglioma.
g)  CARCINOID TUMOUR :
It can arise in the retroperitoneum.
But, it may be metastasis from an undetected primary, 
expression of a mesodernal teratoma,
neoplasm from endodermal cells normally present in this location.
VIII.  RETROPERITONEAL EXTRAGONADAL GERM CELL TUMOURS :
 Primary tumours of extragonadal origin are rare.
 Retropertitoneum is the second most common site of extragonadal germ cell tumours.
 Two school of thoughts exist as to the origin of these neoplasms.
i) Displacement of primitive germ cells during early embryonic migration from the 
yolk sac ectoderm.
ii) Persistence of pluripotent cells in sequestered primitive rests during early somatic 
development. 
 Distinction  between  primary  EGCT  and  metastasis  from  an  undetected  primary 
testicular  tumours  may  be  difficult  which  has  to  be  carried  out  by  careful  physical 
examination, supplemented by the use of high-resolution ultra sonogram.  
 Both  seminomas  and  non-seminomatous  germ  cell  tumours  can  occur  in  the 
retroperitoneum.
Non-seminomatous GCT include embryonal carcinoma. 
Yolk sac tumours, endodernal sinus tumour, teratoma.
Seminomas GCT are common in elderly males.
Non-seminomatous GCT occurs predominantly in female children.
 These tumours lack encapsulation, in contrast to their testicular counterparts, and tend to 
invade or envelope contiguous structures.
IX.  RETROPERIOTONEAL LYMPHOMA :
 Retroperitoneum is a common location for lymphoma.  Both Non-Hodgkin’s lymphoma 
and Hodgkin’s lymphoma can occur in the retroperitoneum. 
 In  children  30%  have  primary  abdominal   presentation.   In  adults  this  type  of 
presentation is less common and generally it is part of a generalized involvement rather 
than being the only site of involvement.
 Retroperitoneal locations include para aortic,  para caval,  interaorto caval,  renal hilar, 
supra hilar regions.
 Lymph nodes are said to be abnormal
i) When enlarged in size > 1 cm in diameter in short axis.
ii) When increased in number.
iii) When characterized by aberrant internal architecture.
Lymphomatous nodes will elevate the aorta.  They can obstruct the infrior vena cava and 
can invade the pelvicalyceal system causing obstructive uropathy.   
X.  TUMO0URS ARISING FROM HETEROTOPIC TISSUE :
1. Extrarenal Wilm’s tumour.
2. Heterotopic adrenocortical carcinoma.
Adrenal or renal cell type undifferentiated adenocarcinoma not involving adrenal gland 
or kidney can arise from heterotopic adrenal tissue and metanephric blastema.
XI.       TUMORS RARELY ENCOUNTERED :
 Extraskeletal Ewing’s Sarcoma.
 Mesothelioma
 Chondrosarcoma
 Clelar Cell Sarcoma
 Synovial Sarcoma
XII.  TUMORS OF UNCERTAIN HISTOGENESIS :
 Granular cell myoblastoma
 Alveolar soft part sarcoma
XIII.  RETROPERITONEAL CYSTS :
 majority of retroperitoneal cysts are benign in nature.  They include,
 Cystic lesion arising from developmental remnants of the urogenital tract.
 Mesenteric cysts
 Teratomatous cysts
 Lymphogeneous cysts
 Serous & mucinous cystadenomas
 Malignant  retro  peritoneal  cystic  lesions  include  serous  &  mucinous 
cystadenocarcinomas.
MUCINOUS CYSTADENOCARCINOMAS :
The  immunological  staining  characteristics  of  these  malignant  lesions  have  patterns 
similar  to  ovarian  mucinous  tumors.   This  genotypic  similarity  may  indicate  similar 
mechanisms in their histogenesis.  
CLINICAL FEATURES OF REROPERITONEAL TUMOUS :
 Signs and symptoms of retroperitoneal tumors are vague.
 Present only when the tumour has attained a large size or by pressure on or infiltration of 
adjacent structures.  This is because retroperitoneum is a potential space and most retro 
peritoneal tumours are expansile growths rather than aggressive infiltrating growths that 
produce  early  clinical  problems and lead to  investigation  early  in  the  course  of  the 
disease.
 Majority have vague abdominal pain/back pain, with a palpable abdominal/pelvic mass.
 Constitutional symptoms such as anorexia, weight loss, fever, fatigue, vomiting may be 
present. 
 Advanced cases may present with 
*  Features of caval compression – 
lower limb edema,
varicocele,
ascites,
dilated abdominal wall veins.
• Genitourinary symptoms
• Venous thrombosis
• Pleural effusion
• Peripheral nerve disorders
• Intra-abdominal bleeding
• Highly vascular tumours may sequester platelets ands produce bleeding disorders. 
Patients may present with features due to paraneoplastic syndrome like 
Liposarcoma  Intermittent hypoglycemia
Germ cell tumour  Pre-cocious puberty
Neurobastoma  Opsoclonic myoclonus
Extra Adrenal Paraganglioma  Symptoms of Catecholamine excess.
CLINICAL EXAMINATION.
 Non tender, firm abdominal mass
 Liver
 Regional lymphnodes
 Scrotal examination
SPREAD OF RETROPERITONEAL TUMOURS
Local Spread : Tumour invading along multiple tissue planes, blood vessels, nerves.
Hematogeneous Spread : Organs involved in the decreasing order of frequency are lung, 
liver, bone, brain.
Lymphatic Spread : Rare < 5% Embyonal rabdomyosarcoma
Lymphangiosarcoma
Epithelial sarcoma
IVESTIGATIONS
Lab Investigations : 
 Blood Urea, creatinine.  Useful to assess renal function. 
 LFT  
 Turmour markers AFP, B-hcG. To R/o germ cell tumours.
 Complete hemogram, peripheral smear useful in cases of lymphomas.
 Plain X-Ray : Shows soft tissue shadow, shifting of bowel loops, calcification if any.
INTRAVENOUS UROGRAM (IVU)
To assess the anatomical and functional status of kidneys as removal of one kidney is 
often required for curative resections, any pressure effect over ureter and its effects.
Contrast CT obviates the need for IVU.
BARIUM MEAL SERIES AND BARIUM ENEMA
Demonstrates displacement or invasion of bowel.  May be occasionally needed in case 
of non-availability of CT.
ULTRASONOGRAM (USG):
Provides inadequate information in 30% due to interference from intraluminal gas.  It 
may show mass,  solid or cystic and secondary changes in the urinary tract.
Contrast enhanced (oral & intravenous) CT abdomen (CECT) :
 Best imaging modality for assessing retroperitoneal lymphadenopathy.
 Shows exact site and size of the tumour.
 Depicts anatomic changes secondary to its growth
 Tumour invasion of adjacent structures demonstrated or suggested
 Most retroperitoneal tumours appear as soft tissue masses with focal areas of necrosis 
but does not predict the histologic type or grade of sarcoma.
 Contrast CT obviates IVP
 CT guided core biopsy, FNA can be taken.
MRI MAGNETIC RESONANCE IMAGING
Its advantages over CT scan are,
 Spatial assessment is better due to multiplanar capability.
 Clear view of vascular structures obtained without contrast.
 Demonstrates the extent of recurrent tumour
 Identifies the presence (or) absence of lymphadenopathy.
 Greater accuracy of defining tumour extent and respectability.
POSITRON EMISSION TOMOGRAPHY (PET SCAN)
 It is complementary to conventional staging modalities for staging.
 It  is helpful in differentiating benign from malignant soft tissue masses.  A tumour – 
background ratio greater than 3 is highly predictive of malignancy.
 The degree of FDG uptake correlates with the grade of the sarcoma and can guide the 
biopsy to be taken from the region with the highest grade.
 It  is  useful  in  monitoring  the  response  to  therapy  and in  the  evaluation  of  residual 
masses after therapy.
ARTERIOGRAPHY
Reveals the extent of the lesion, tumours blood supply, displacement of major vessels or 
pressure effects.
Considered in large lesions.
INFERIOR VENACAVOGRAM (IV Gram)
It may show vena caval obstruction.
RETROPERITONEOSCOPY:
Useful to diagnose retropritoneal masses and to take visually guided biopsies from the 
more representative area.
Used when CT / USG guided biopsy fails to establish a definite diagnosis.
In  future,  retroperitoneoscopy  with  visually  guided  biopsy  will  replace  CT  guided 
biopsy.
CHEST X-RAY OR CT THORAX
To assess pulmonary metastases, pleural effusion, assessing mediastinal lymphadenopathy.
AJCC STAGING FOR SOFT TISSUE SARCOMAS 
G  - Histologic Grade 
Gx - Grade cannot be assessed
G1 - Well differentiated
G2 - Moderately differentiated
G3 - Poorly differentiated
G4 - Undifferentiated
T Primary tumour Site
Tx - Primary tumour size can not be assessed
T0 - No evidence of primary tumour
T1 - Tumour < 5 cm
  T1a - Superficial tumour
  T1b - Deep tumour
T2 - Tumour 5cm > greater
  T2a - Superficial  tumour
  T2b - Deep tumour
N Regional Nodes
Nx - Regional nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Regional lymphnode metastasis
M, Distant Metastasis
Mx - Presence of distant metastasis cannot be assessed
Mo - No distant metastasis
M1 - Distant metastasis present
Staging
Stage I G1-2 T1a, 1b, 2a, 2b No Mo
Stage II G3-4 T1a, 1b, 2a No Mo
Stage III G3-4 T2b No Mo
Stage IV Any G Any T N1 Mo
Any G Any T Mo M1
TREATMENT OF RETROPERITONEAL SARCOMAS
The significant advances in multimodality therapy of extremity sarcomas have not been 
matched by similar progress in the management of retro peritoneal sarcomas.
Retroperitoneal sarcomas have a poor outcome. reasons being,
 Inability to diagnose these tumours at an early stage.
 Rarely cause significant symptoms until they achieve large size and even then symptoms 
are generally vague and nonspecific.
 Close relation to major blood vessels.
 Post op. RT difficult.
PREPARATION
1) Adequate blood should be arranged
2) Consent for removal of adjacent organs
3) Consent for faecal / urinary diversion.
4) Preoperative full  bowel preparation is  necessary as limited resection of  the colon or 
rectum is commonly required.
APPROACHES
i) Transabdominal approach
ii) Retroperitoneal or flank approach
iii) Thoraco abdominal approach
I) TRANSABDOMINAL APPROACH
Advantages :
 Allows enbloc resection of involved organs.
 Early control of the vascular supply to the tumour
II) RETROPERITONEAL OR FLANK APPRAOCH
Advantages :
 Post operative ileus is brief.
 Continued use of GIT to deliver nutritional support.
 Avoids handling of intestines and hence adhesions.
 Intraoperative heat loss and fluid loss is less.
 Post operative pneumonia and atelectasis is less.
 Abscess if it develops is interstitial and not intraperitoneal.
Disadvantages :
 Less satisfactory exposure in resection of adjacent organs.
III) thoraco abdominal approach
It is indicated if the tumour is in the upper retroperitoneum or invading the diaphragm.
 Localised tumours should be removed enbloc with 1-2cm margins and enbloc resection 
of the involved organ most commonly the kidney, tail of pancreas or colon.
 Apparent capsule is usually a pseudocapsule containing normal as well as neoplastic 
cells.  For curative resection, remove the tumour with surrounding clear margins. We 
should not  remove the  tumour  from its  pseudocapsule,  because though dissection  is 
easy, recurrence is almost certain.
 Retroperitoneal  sarcomas  are  often  fixed  as  they  invade  muscles  of  the  posterior 
abdominal wall which are themselves immobile.
 Fixation  is  not  a  sign  of  unrestectability  unless  there  is  extensive  involvement  of 
irreparable or unremovable structures.
 Resectability rate varies between 30% - 100%.
 When  retro  peritoneal  sarcoma  is  encountered  unexpectedly  at  laparotomy,  careful 
incisional  biopsy  with  minimal  disruption  of  surrounding  tissue  planes  should  be 
performed. Atrea of the biopsy should be isolated to prevent tumour spillage into the 
peritoneal cavity. When diagnosis is confirmed, wide excision carried out at the earliest.
RESECTION RATE
 It is 60% depending on the outlook of the surgeon.
 Highest resectability rate for liposarcoma and neurogenic sarcomas.
 Least resectability rate for leiomyosarcomas.
 For extensive low grade tumours, subtotal or palliative resections are beneficial.
 Complete resection rate 65% for Primary tumour, 44% for recurrent tumour.
EXENT OF RESECTION
Resection of adjacent organs is necessary in 75% of patients for complete removal of 
retroperitoneal sarcomas.
Kidney  and  adrenals  are  the  organs  most  commonly  resected  in  curative  resection 
followed by colon, pancreas, small bowel.
Radical lyphadenectomy is not indicated as the lymphnode metastasis is <5%.
Partial Resection.
 No survival benefit
 Used only for pain relief (or) bowel obstruction.
OPERATIVE MORTALITY :
It should be less than 5% with modern anaethesia and support.
OPERATIVE MORBIDITY
Depends on the extent of resection and adjacent organs resected.
Common problems are small intestinal and colonic ileus, 
 Perforation,
 Fistulas,
 Abdominal abscesses.
 Local Recurrence rate 40% to 85%.
PROGNOSIS & SURVIVAL :
Prognosis depends on two important factors :
a) Completeness of tumour resection.
b) Histological grade of tumour rather than histologic type.
Complete resection provides long term survival.
5 year survival rate after complete resection is 32-100%.
60-90% for low grade tumours,
15-50% for high grade tumours,
Overall  survival  including partial  resection is  10%-50% at  5  years,  10%-20% at  10 
years.
Based on histological grade
If low grade - Recurrence occurs late, better survival
If high grade - Recurrence occurs early, poor survival
Retroperitoneal  sarcomas  are  rarely  totally  cured  because  survival  intervals,  even  if 
totally resected continue to decline beyond 15 years.
Recurrences  occur  in  50%  of  patients  often  in  the  original  tumour  bed  and  often 
resectable.  So, careful long term follow up and aggressive surgical resection of recurrences 
when  complete  resection  is  possible.  Tumours  often  becomes  less  differentiated  and  more 
aggressive with each recurrences, with short tumour free intervals.
Median time for recurrence – 19 mo for high grade and 44mo  for low grade.
CAUSE OF DEATH is mainly due to local invasive effects of the tumorus.
RADIOTHERAPY 
 It is used as an adjuvant treatment following surgery as it is not possible in majority to 
obtain tumour clearance by surgical resection alone.
 Normal tissue tolerance to radiation is much lower in the abdomen and retroperitoneum 
than in  the  extremities.  Extremity  tumours  are  treated with 6000 cGY or more.   In 
contrast, the small bowel can tolerate only 4500-5000 cGYand the liver and kidney, even 
less.
 In order to limit tissue toxicity, IORT (Intra Operative Radiotherapy) has been used. 
Here, the sensitive structures are moved out of the field while a single high dose or 
radiation is administered directly to the tumour bed.  IORT is costly, logistically difficult 
and  has  its  own complications  such  as  neurotoxicity  and available  only  in  selected 
centers.
RADIATION SENSITIZERS :
 As the normal tissue tolerance of the retroperitoneum is limited, radiation sensitizers are 
being investigated to improve the effectiveness of EBRT (External Beam Radiotherapy).
 Iododeoxyuridine (IUDR) is the commonly used radiosensitizing agent.  It is 100 times 
more effective than doxorubicin as a radiation sensitizer in vitro, although it does not 
have doxorubicin’s direct cytotoxic effect.
 Studies of IUDR and EBRT in unresecetable sarcomas document impressively high rates 
of local control without surgery.
 Preoperative treatment with IUDR & radiation allows complete excision of gross tumour 
for most patients with retroperitoneal sarcomas and toxicity of this protocol has been 
acceptable.
CHEMOTHERAPY :
 Post operative adjuvant chemotherapy is of no benefit for retro peritoneal sarcomas and 
is poorly tolerated by patients, who have undergone a major intra-abdominal procedure 
with resection of multiple organs.
 Use of granulocyte macrophage colony stimulating factor has been associated with good 
response.
 Preoperative intra arterial chemotherapy is limited by the absence of a single feeding 
vessel in most retro peritoneal tumours.
 Complete Response rate of 15-35% have been reported with the use of adriamycin as a 
single agent.
TREATMENT OF RETROPERITONEAL GERM CELL TUMOURS
It is dependent on both the histologic type and size of the tumours.
Seminomas < 5cm, no metastasis  Radiotherapy 18-40 Gy.
Seminomas > 5cm  Initially chemotherapy, irradiate 
    residual masses after chemotherapy.
Benign teratomas  Surgical resection.
Non-seminomastous Germ Cell tumours   Initially chemotherapy.
     Residual masses resected 
     surgically.
CHEMOTHERAPY REGIMENS :
PVB - Cisplatin VAB-6  - Vinblastine
Vinblastine Actinomycin –D
Bleomycin Bleomycin
Cisplatin
BEP - Bleomycin POMB - Cisplatin
Etoposide Vincristine
Displatin Metotrexate
Bleomycin
ACE - Actinomycin D
Cyclophosphamide
Etoposide.
METASTATIC RETROPERITONEAL TUMOURS
Metastatic tumours in the retroperitoneum develops by two main routes.
i) Local extension.
ii) Lymphatic spread.
i) LOCAL SPREAD:
Local extension of tumour principally occurs in
Pancreatic carcinoma.
Primary bone tumours notably sacrococcygeal chordoma.
II) LYMPHATIC SPREAD 
Most common mode of spread to retroperitoneum.
Principal primary sites being.
Testes, Urinary bladder
Prostate Uterine cervix
Pancreas Endometrium
Kidney
Other primary sites include
Ovary Lung
Adrenals Breast
Stomach Melanoma
Colon
Diagnosis by USG, CT, FNAB.
Diagnosis based on presence of ‘alien’ calls, which are cells not normally indigenous to 
normal lymphnode constituents.
Cytologic appearance is similar to that described in their primary locations.
TREATMENT OF METASTATIC RETROPERITONEAL TUMOURS
Most  of  metastatic  reroperitoneal  tumours  are  treated  by  chemotherapy  regimens 
depending on the primary site.
TREATMENT OF TESTICULAR METASTASIS TO RETROPERITONEAL NODES.
TREATMENT OF NON-SEMINOMATOUS GERM CELL TUMOUR METASTASIS
LOW STAGE DISEASE
Stage I T1– 3 N0 M0
Stage IIA T1-3N1M0
Stage II B T1-3N2M0
 Retroperitoneal lymph node dissection (RPLND) followed by adjuvant chemotherapy 
BEP 2 cycles. (or) Primary Chemotherapy BEP for 3 cycles.
HIGH STAGE DISEASE
Stage II C T1 N3 M0
Stage III Any T any N M1
Good Risk disease
↓
Chemotherapy BEP
3 cycles
↓
Residual mass RPLND
GCT               Teratoma,
                         Fibrosis
Salvage CT   Observation.
            (VIP)
Poor risk disease
↓
Chemothrapy
↓
Ifosfamide substitutes Etoposide
↓
Poor response to CT
↓
Salvage CT (VIP)
TREATMENT OF RETROPERITONEAL NODES FROM SEMINOMA
Stage I : Abdominal radiotherapy 25 Gy to para
Aortic nodes.
Stage II A, B : Adbominal radiotherapy 150 cGy per day
5 days per week for 6 weeks.
Chemotherapy if involved nodes are close to 
kidney.
Stage IIIc, III : Chemotherapy (BEP)
Post chemotherapy residual mass if > 3 cm surgical 
resection.
CHEMOTHERAPY REGIMENS
BEP regimen
B Bleomycin - 30 U iv day 2,9,16
E Etoposide - 100mg/m2 ivday – 5
P cisplatin - 20mg/m2 iv day 1-5
Ifosfamide - 1.2g/m2 iv day 1-5
RETROPERITONEAL LYMPHNODE DISSECTION (RPLND)
 This is  a  highly sensitive  though rigorous method of  detecting involvement of  retro 
peritoneal lymphnodes.
 Predominantly  used in  non-seminomaous tumors,  because 20-30% of testicular  non-
seminomas with normal CT abdomen have RPLN metastases.
 Risk of metastases can be predicted by the vascular invasion in the primary tumour.
 The extent of lymph node involvement is predictive for relapse at other sites and can be 
used as a basis for considering adjuvant chemotherapy.
TECHNIQUES
1) Bilateral RPLND : Suprahilar, infrahilar
2) Modified RPLND : For right and left testicular tumours.
3) Nerve sparing RPLND.
Surgical principles critical to perform RPLND safely :
i) Indepth understanding of retro peritoneal anatomy and be able to recognize common 
variations and their implications.
ii) Excellent exposure of the retroperitoneum.
iii) Thorough lymphadenectomy using ‘split & roll’ technique.
APPROACHES
1) Transabdominal This approach is most commonly 
employed
2) Thoracoabdominal This approach is used for suprahilar 
dissections.
3) Laparascopic This approach is the noval developing 
technique.
Laparoscopic RPLND :
This technique is used for Clinical Stage  I and II testicular cancers.  And it is found to 
be superior to open surgery in terms of surgical efficiency, morbidity and costs, whereas the 
therapeutic efficiency is equal.
SPLIT AND ROLL TECHNIQUE
Allows enbloc removal of the nodes. The lumbar vessels must be divided twice, first at 
the wall of the great vessels and again as they enter the foramina alongside the vertebral bodies.
Important aspect of performing nerve-sparing RPLND
Identification and preservation of 
i) Sympathetic chains bilaterally
ii) Postganglionic sympathetic nerves arising from the sympathetic chains.
iii) Hypogastric plexus which is the anastomosing network of nerve fibers anterior to 
lower aorta.
The  most  important  nerves  are  those  arising  from  L3  and  L4  ganglion,  which  are 
essentials for preserving antegrade ejaculation.
COMPLICATIONS OF RPLND
Major complications include 
 Small bowel obstruction
 Lymphocele
 Wound dehiscence
Pulmoary  complications  in  thoracoabdominal  approach  which  include  atelectasis, 
prolonged chest tube drainage, need for increased post operative analgesia.
Loss of antegrade ejaculation and consequently potential infertility.
It is inevitable after the bilateral RPLND
It is reduced by nerve sparing RPLND.
RETROPERITONEAL LYMPHOCELE
 It is a post operative complication following RPLND.
 Usually develops within 10-21 days of surgery
 It can occur in both retroperitoneum and peritoneal compartments but retroperitoneal 
location is more commion.
Investigations :
CT & MRI : Shows encapsulated fluid collections fo varying complexity.
Distinction between lymphoceles,  cystic tumour recurrence and other abnormal fluid 
collections can be difficult.
USG : Anechoic appearance similar to simple cysts.
Distinction from an abscess, hematoma, urinoma, fluid – filled bowel is often difficult, 
especially if internal debris is present.
Because of poor specificity of CT, MRI, USG ; percutaneous aspiration is often required 
for definitive diagnosis.
Treatment :
Small anechoic lymphoceles often resolve spontaneously.
Large, echogenic lymphoceles may require 
- Drainage
- Sclerosing therapy
- Surgical resection.
TREATMENT OF LYMPHOMAS
Modified Ann Arbor Staging for Hodgkin’s Lymphoma
Stage I  : Single lymphnode region (1) or one extra lymphatic site (1E)
Stage  II :  Two  (or)  more  lymphnode  regions,  same  side  of  the  diaphragm (11)  or  local 
extralymphatic extension plus one (or) more lymphnode regions on same side of diaphragm 
(11E).
Stage  III :  Lymphnode  regions  on  both  side  of  the  diaphragm  (111),  which  may  be 
accompanied by local extra lymphatic extension (IIIE) (or) Spleen (111s).
Stage IV : Diffuse involvement of one (or) more extra lymphatic organ (or) site.
B Symptoms : Presence of at least one of the following.
1) Weight loss > 10% during 6 months
2) Recurrent unexplained fever > 38OC
3) Recurrent night sweats
OVERVIEW OF TREATMENT OF HODGKIN’S LYMPHOMA
Stage Ia, IIa Low Bulk ABVD x 2 + IRRT
Any stage with B 
symptoms (or) stage 
III or IV
Low Bulk ABVD untill 2 cycles 
past complete 
response (Min – 6 
cycles Max – 8 
cycles.)
Any Stage Bulky ABVD x 6 +_ IRRT
IRRT – involved Region Radiotherapy
Bulky - > 10cm largest diameter of any single mass or mediastinal mass ratio > 1/3 largest 
transthoracic diameter.
CHEMOTHERAPY REGIMNS USED FOR HODGKIN’S LYMPHOMA 
1) ABVD
A: Adriamycin – 25mg / sq.meter IV  1 & 15
B : Bleomycin – 10 units / sq. meter IV 1 & 15
V : Vinblastine – 6mg / sq. meter IV 1 & 15
D : Dacarbazine 375mg/ sq. meter IV 1 & 15
Repeat every 28 days for 6 cycles 
2) MOPP
M : Mechlorethamine – 6mg / sq. meter IV 1 & 8
O : Oncovin – 1.4mg / sq. meter IV 1 & 8
P : Pro carbazine – 100mg / sq. meter PO 1-14
P : Prednisolone – 40mg / sq. meter PO 1-14.
Repeat every 28 days for 6 cycles.
3) MVPP
Mechlorethamine, Vinblastine, Procarbazine, Prednisolone 
4) ChlVPP
Chlorambucil, Vinblastine, Procarbazine, Prednisolone.
TREATMNT OF NON-HODGKIN’S LYMPHOMA
CLASSIFICATION OF NHL
I) Low Grade NHL
 Small lymphocytic
 Follicular predominantly small cell type
 Follicular mixed cell type
II) Intermediate Grade NHL
 Follicular predominantly large cell type 
 Diffuse – small cell, large cell (or) mixed type
III) High Grade NHL
 Large Cell immunoblastic
 Lymphoblastic
 Burkitt’s lymphoma
TREATMENT OF LOW GRADE NHL
Stage I & II – Radiotherapy
3600 – 4500 cGY
100 – 150 cGY / day for 5 days / wk for 6 wks
Limited abdominal NHL – Para aortic radiation.
Stage III & IV – Chemotherapy.
TREATMENT OF INTERMEDIATE AND HIGH GRADE WHL 
For all Stages – Chemotherapy
CHOP Regimn
C : Cyclophosphamide 750mg / sq. meter IV on day 1
H : Doxarubicin  50mg / sq. meter IV on day 1
O : Oncovin 1.4mg / sq. meter IV on day 1
P : Prednisolone 100mg orally for days 1-5
Repeat every 21 days for 6 cycles.
ROLE OF SURGERY IN RETROPERITONEAL LYMPHOMAS
If lymphomas found accidentally on laprotomy
If  localized resect fully.
If diffuse, biopsy alone taken and margins of tumour marked by clips.
MATERIALS AND METHODS
The  clinical  material  used  in  this  study  consists  of  26  patients  of  suspected 
retroperitoneal tumours in Govt. Stanley Hospital during the period from July 2003 to March 
2006.
MATERIALS
1) Clinical evaluation of
Age and sex incidence
Presenting symptoms
Clinical examination.
2) Investigations
Routine haematological and biochemical investigations
Peripheral smear
HIV – ELISA test
Chest X-ray
USG abdomen
Contrast CT abdomen
IVU
Lymph node biopsy
Laparoscopy
BMFT / BA enema
Colonoscopy
METHODOLOGY
All patients are thoroughly examined and necessary investigations done.
Treatment  modality  is  then  planned  according  to  the  investigation  report  and  are 
managed accordingly.
Surgically resected specimens are sent for histopathological examination.
Patient immediate post operative period was studied.
 
OBSERVATION AND RESULTS
The following observations were made in our study on retroperitoneal tumours.
DISTRIBUTION OF DIFFERENT TYPES OF RETROPERITONEAL TUMOURS
Type Number Percentage
Primary Retro 
peritoneal tumours
16 61.5
Retroperitoneal 
lymphomas
6 23.1
Secondary metastasis 4 15.4
Total 26
 Primary  retro  peritoneal  tumours  are  the  most  common  type  followed  by  retro 
peritoneal lymphomas and secondaries.
AGE INCIDENCE OF RETROPERITONEAL TUMOURS
Age (yrs) Number Percentage
20-30 6 23.1%
30-40 8 30.8%
40-50 4 15.4%
50-60 6 23.1
60-70 2 7.6
54% of retro peritoneal tumours occurred in age group of 20-40 years.
SEX INCIDENCE OF RETROPERITONEAL TUMOURS
Sex Number Percentage
Male 11 42.3%
Female 15 57.7%
The male : female ratio was 1:1.36.
CLINICAL PRESENTATION OF RETROPERITONEAL TUMOURS
Symptoms
Number Percentage
Incidental 2 7.7
Abdominal mass 24 92.3
Abdominal Pain 15 57.7
Loss of Weight 22 84.6
Loss of Appetite 12 46.1
Urinary Tract 
symptoms
8 30.8
GI Symptoms 2 7.7
Oedema / Pain 2 7.7
Emergency - -
92% of patients presented with abdominal mass.
Other commonly noted symptoms are pain, loss of weight and loss of appetite.
DISTRIBUTION OF RETROPERITONEAL LYMPHOMAS
Type As part of Gen. 
Lymphadenopthy
Localised retro 
peritoneal 
involvement
Hodgkin’s 1 -
Non-Hodgkin’s 4 1
Total 6
Majority of retro peritoneal lymphomas are of non-Hodgkin’s type occurring as a part of 
generalized lymphadenopathy.
INVESTIGATIONS DONE
Investigations Number
USG – Abdomen 26
Contract CT abdomen 26
X-ray chest 26
Lymphnode biopsy 6
IVU 8
Barium enema 2
Laproscopy 1
Colonoscopy 1
TREATMENT OFFERED
Type of surgery Number
Operative
Complete Excision of Tumour only 6
Complete Excision of Tumour + (R) 
Hemicolectomy
1
Complete excision of tumour + 
vascular graft
Nil
Incomplete excision (Debulking) 6
Non – Operative
↓
Chemotherapy
Lymphomas 6
Metastatic Tumours 4
Tumours found inoperable 
by investigations
3
POST OPERATIVE COMPLICATIONS
Post op complications Number
Prolonged Paralytic ileus 2
Wound infection 1
Death 1
Total 4
One patient died due to respiratory complications.
CLEARANCE IN SURGICAL RESECTED TUMOURS
Total No. of Patients 7
Positive Tumour margin 1
Samples from bed positive 2
3 patients had histologically positive margins and one of them presented 2 years later 
with recurrence.
HISTOLOGY DISTRIBUTION
Type Number
Primary Liposarcoma 9
Fibrosarcoma 4
Leiomyosarcoma 1
Neuro ecto dermal 
tumour
2
Secondary Granulosa cell tumour 
of ovary
1
Adenocarcinoma 3
Lymphomas Non-Hodgkin’s 5
Hodgkin’s 1
Majority of the retroperitoneal tumours are of primary type of which liposarcoma is the 
commonest followed by fibrosarcoma.
Of the secondaries, adenocarcinoma was the commonest type in our study.
SELECTED REPORTS EVALUATING SURGICAL TREATMENT OF PRIMARY 
RETROPERITONEAL TUMOURS
Study
No. of 
Patients
Complete 
Resection
5 – year Local 
Recurrence
5 – year 
survival
Lewis et al (1998) 500 80% 59% 70%
Jagues et al (1990) 1143 65% 49% NR
Stoeckle et al (2001) 165 65% 48% 46%
Hassan et al (2004) 97 78% 44% 51%
Alvavenga et al (1991) 120 25% 80% 29%
Sunger et al 1993 83 NR NR 54
Karakonsis et al (1996) 57 100 42 66
ALJEIRAN RA, LOPEZ GC, HERVA GA ET AL.
Rev Inst. Nal. Cancercol. (Men) 1977 43(4) 194-199.
Most common histology : Liposarcoma 55%.   Leumyosarcoma 16%.
Complete resection rate 71%
Partial resection rate 11%
CHRISTOPHER WONDLHAM, Peter WT Pristel et al
Cancer control Jan / Feb Vol. 12, No.1 (35/36)
Most common histology
Lipo sarcoma 41%
Lecomyosarcoma 28%
MFH 7%
Fibrosarcoma 6%
MPNST 3%
Most common presentations : Abdominal mass.
The incidence is equal between both sexes.
BURTON L. ESENBERG ET AL
State of the science June 2002.
Most common histology liposarcoma 40%
Leiomyosarcoma 30%.
Complete resection rate 50-60%.
LEWIS JJ LAING D, W ORDEROFF JM, BRENNAN MF ET AL
Dept. of Surgery
Memmorial Sloan Kettering Cancer Centre, New York.
Most common histology : MFH : 40%
Liposarcoma : 25%
TORNI FERRARIO, CONSTANTINE P KARAKOUSIS ET AL
Archives of Surgery Vol. 138, No.3, Mar. 2003.
Complete resection rate 95%
99% primary tumours
90% for recurrent tumours
Local recurrence 41%.
OBSERVATION AND ANALYSIS
In this study of 26 patients with retroperitoneal tumours following observations were made. 
1. Majority of the retroperitoneal tumours occurred in the age group 20-40 years.
2. The incidence was almost equal in both male and females. This is consistent with the study 
conducted by Christopher Wondlham, Peter WT prisstel et al. Cancer control Jan / Feb Vol.  
12, No.1 (35/36)
3. Primary retro peritoneal tumours are the most common type followed by retro peritoneal 
lymphomas and then secondaries.
4. Abdominal mass was the  most  common initial  presentation.  This  is  consistent with the 
study conducted by Christopher Wondlham, Peter WT prisstel et al. Cancer control Jan / 
Feb Vol. 12, No.1 (35/36)
5. Majority of retroperitoneal lymphoma are of non-Hodgkin’s type.
6. Surgery  was  the  primary  modality  of  treatment  in  retroperitoneal  sarcomas  and 
chemotherapy was given to retro peritoneal lymphomas and secondaries.
7. Liposarcoma was the most common histological subtype encountered in our study.  This is 
consistent  with  the  studies  conducted  by  Aljeiran  Ra,  Lopez  Gc,  Herva  Ga  Et  Al, 
Christopher Wondlham, Peter WT Pristel et al, Burton l. Esenberg et al.
8. The complete resection rate in our study was 53.8%. This is less than the studies conducted 
by Lewis et al, Jagues et al but similar to the studies conducted by Burton L. Esenberg et al.
DISCUSSION
Retroperitoneal  tumours  are  relatively  rare  accounting  for  less  than  1% of  tumours 
encountered in our hospital.
RETROPERITONEAL TUMOURS PRIMARY
Primary retro peritoneal tumours accounts for 61.5% of retroperitoneal tumours.
Majority of them presented with abdominal mass followed by loss of weight and loss of 
appetite and pain.
Two patients had symptoms of sub acute intestinal obstruction and another two had pain 
radiating down the leg.
USG abdomen and contrast CT abdomen was done in all patients.
Three  patients  had  growth  closely  related  to  major  vessels  and  were  decided 
unresectable.
Seven Patients had complete excision of the tumour mass and debulking was done in 6 
patients and were followed up with radiotherapy.
In one patient, resection and anastomosis of small bowel  and Rt hemicolectomy was 
done along with the tumour. 
Majority of the tumours were liposarcoma, the next  common being fibrosarcoma.
One patient died on 17th post operative day die to respiratory complications.
RETROPERITONEAL LYMPHOMA
Majority of the retroperitoneal lymphomas are of NHL, intermediate grade type.
Lymphnode biopsy was done in all cases to confirm the diagnosis.
Complete  haemogram,  peripheral  smear,  ELISA,  USG  abdomen  and  contrast  CT 
abdomen were also done.
Five  patient  had  non-Hodgkin’s  lymphoma  and  were  treated  with  CHOP regimen 
chemotherapy.
One patient had Hodgkin’s lymphoma and was treated with MOP regimen.
Chemotherapy was found to be successful and majority of patients responded well.
METASTATIC RETROPERITONEAL TUMOURS
Majority  of  retroperitoneal  metastasis  in  this  study  were  adenocarcinoma  and  were 
treated with chemotherapy according to the primary histology.
Most of the patients did not come for followup so recurrence, mortality and morbidity 
could not be assessed.
                                         CONCLUSION
In this study of 26 patients with retroperitoneal tumours following conclusions were made
1) Majority of the retroperitoneal tumours occurred in the age group 20-40 years.
2) The incidence was almost equal in both male and females.
3) Primary retroperitoneal tumours are the most common type followed by retro peritoneal 
lymphomas and then secondaries.
4) Abdominal mass was the most common initial presentation.
5) Majority of retroperitoneal lymphoma are of non-Hodgkin’s type.
6) Surgery  was  the  primary  modality  of  treatment  in  retroperitoneal  sarcomas  and 
chemotherapy was given to retroperitoneal lymphomas and secondaries.
7) Liposarcoma was the most common histological subtype encountered in our study.
PROFORMA
Name : Age : Sex : IP No.
Occupation : D.O.A. :
Address : D.O.S. :
D.O.D.:
CHIEF COMPLAINTS AND THEIR DURATION
Abdominal mass
Abdominal pain
Loss of weight
Loss of appetite
Nausea and vomiting
Constipation
Fever
Urinary tract symptoms
Lower limb edema / pain
PHYSICAL EXAMINATION
Built
Nourishment
Anaemia
Lymphadenopathy
Pedal edema
Swelling elsewhere
Café lait spots
Abdominal examination
Character of the swelling Site :
Size :
Shape :
Plane :
INVESTIGATIONS
Routine blood and urine examinations
Complete haemogram
Peripheral smear
ELISA
X-ray chest
FNAC
Lymph node biopsy
USG – abdomen
Barium enema / colonoscopy
Contrast CT abdomen
TREATMENT GIVEN
IMMEDIATE POST OPERATIVE FOLLOWUP
HPE REPORT
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